Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma(MEDI2228) | completed | Phase 1 | 107 | MedImmune LLCINDUSTRY | 4 | Mar 28, 2022 | clinicaltrials |
| NCT04163107 | Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma(MYELOMA-HCQ) | completed | Phase 1 | 19 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 18, 2022 |
| clinicaltrials |
| NCT03464916 | Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04280328 | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 7 | Corvus Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02293109 | Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma | completed | Phase 1 | 10 | Mehrdad Abedi, MDOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03974243 | Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 9 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 9, 2022 | clinicaltrials |
| NCT02730312 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | completed | Phase 1 | 120 | Xencor, Inc.INDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03925935 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | completed | Phase 1 | 42 | Angiocrine BioscienceINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02514239 | Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 2 | Feb 24, 2022 | clinicaltrials |
| NCT01583283 | Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | completed | Phase 1 | 38 | CelgeneINDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT04955340 | A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat | completed | Phase 1 | 5 | 4SC AGINDUSTRY | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03111992 | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma | completed | Phase 1 | 26 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 9, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04811898 | A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment(LNA-i-miR221) | completed | Phase 1 | 17 | Azienda Ospedaliera Universitaria Mater Domini, CatanzaroOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT02613598 | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 | 15 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE(BV-ICE) | completed | Phase 1 / Phase 2 | 53 | The Lymphoma Academic Research OrganisationOTHER | 2 | Dec 7, 2021 | clinicaltrials |
| NCT01535924 | Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 26 | Beth ChristianOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT01038388 | A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 | 30 | Emory UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT01445535 | Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 3, 2021 | clinicaltrials |
| NCT02660281 | URMC Related Haplo-identical Donor BMT(HaploOnly) | completed | Phase 1 | 74 | University of RochesterOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT00000689 | Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | completed | Phase 1 | 18 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Nov 2, 2021 | clinicaltrials |
| NCT01780662 | Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Oct 28, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT02808442 | Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia(PALL) | completed | Phase 1 | 13 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 8, 2021 | clinicaltrials |
| NCT01381692 | Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2021 | clinicaltrials |
| NCT02746952 | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia(CALM) | completed | Phase 1 | 25 | Institut de Recherches Internationales ServierOTHER | 4 | Oct 1, 2021 | clinicaltrials |
| NCT02646085 | Multiparametric Imaging in Multiple Myeloma | completed | Phase 1 | 10 | Yingbing WangOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03958656 | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2021 | clinicaltrials |
| NCT01965353 | A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma(PanRVD) | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01723020 | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | completed | Phase 1 | 107 | Kartos Therapeutics, Inc.INDUSTRY | 3 | Sep 2, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT01767766 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 90 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 23, 2021 | clinicaltrials |
| NCT02481934 | Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma(NK-VS-MM) | completed | Phase 1 | 5 | Joaquín Martínez López, MD, PhDOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT00061425 | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | completed | Phase 1 / Phase 2 | — | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT00596804 | Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 39 | Gilead SciencesINDUSTRY | 2 | Aug 18, 2021 | clinicaltrials |
| NCT00285428 | Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 82 | Gilead SciencesINDUSTRY | 1 | Aug 17, 2021 | clinicaltrials |
| NCT03383055 | CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig | completed | Phase 1 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00421395 | Safety Study of NHL With 90Y-hLL2 IgG | completed | Phase 1 / Phase 2 | 59 | Gilead SciencesINDUSTRY | 2 | Aug 16, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT00546793 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | completed | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2022source: clinicaltrials